secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0000885725-23-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific beats Q3 estimates; raises FY 2023 adjusted EPS guidance to $1.99-2.02
--------------------------------------------------------------------------------

- Q3 net sales $3.527B (+11.2% reported, +10.2% organic); beat guidance of 8.5-10.5% reported and 7-9% organic.
- GAAP EPS $0.34 (vs guidance $0.21-0.25); adjusted EPS $0.50 (vs guidance $0.46-0.48), up from $0.43 a year ago.
- Cardiovascular sales $2.185B (+11.6% reported); MedSurg $1.341B (+10.6%); U.S. grew 8.5%, Asia-Pacific 14.8% reported.
- FY 2023 guidance raised: organic sales growth ~11%; GAAP EPS $1.00-1.04; adjusted EPS $1.99-2.02 (prev. $1.94-1.98).
- Announced agreement to acquire Relievant Medsystems (Intracept system) for vertebrogenic pain; terms not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/0000885725-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/bsx-20231026.htm
  HTML page:      https://secwatch.observer/filing/0000885725-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer